<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596712</url>
  </required_header>
  <id_info>
    <org_study_id>CQGE031A1101</org_study_id>
    <nct_id>NCT01596712</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Following Subcutaneous Injections of QGE031 in Japanese Atopic Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and
      immunogenicity of QGE031 in Japanese atopic male subjects in order to determine the
      eligibility of Japanese patients in subsequent clinical studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>Day 113</time_frame>
    <description>Adverse events will be determined by evaluating clinical, laboratory evaluations, impact on vital signs and impacts on ECGs and other safety assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QGE031 serum concentration</measure>
    <time_frame>Pre-dose, 2, 4, 12, 24, 48, and 96 h post-dose, Days 8, 15, 22, 29, 43, 57, 71, 85, 99 and 113</time_frame>
    <description>Blood will be collected for the determination of serum QGE031 concentrations. Cmax, Tmax, Area Under the curve (AUC), terminal half-life of serum QGE031. These parameters will be determined using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free and total IgE serum concentrations</measure>
    <time_frame>Pre-dose, 2, 4, 12, 24, 48, and 96 h post-dose, Days 8, 15, 22, 29, 43, 57, 71, 85, 99 and 113</time_frame>
    <description>Blood will be collected to measure serum IgE concentrations. Cmin, Tmin, and percent decrease of free IgE serum concentration will be determined. Cmax, Tmax, and percent increase of total IgE serum concentration will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FcεRI expression and IgE binding on basophiles</measure>
    <time_frame>Pre-dose, 2, 24, 48, 96 h post-dose; Days 8, 15, 22, 29, 43, 57, 71, 85, 99, and 113</time_frame>
    <description>Blood will be collected to measure FcεRI expression and IgE binding on basophiles. Lots of individual values and mean values over time will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (Anti-QGE031 antibody in serum)</measure>
    <time_frame>Pre-dose, Days 29, 57 and 113</time_frame>
    <description>Blood will be collected to measure Immunogenicity. The number and percentage of subjects producing anti-QGE031 antibody will be presented.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>QGE031 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QGE031 Dose 1: subcutaneous injection, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QGE031 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QGE031 Dose 2: subcutaneous injection, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QGE031 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QGE031 Dose 3: subcutaneous injection, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to QGE031 : subcutaneous injection, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QGE031</intervention_name>
    <description>QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.</description>
    <arm_group_label>QGE031 Dose 1</arm_group_label>
    <arm_group_label>QGE031 Dose 2</arm_group_label>
    <arm_group_label>QGE031 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male Japanese subjects who are atopic as determined by an in vitro test (CAP-RAST or
             MAST test)

          -  Serum IgE level must be equal to or greater than 30 IU/mL at screening.

        Exclusion Criteria:

          -  Poorly controlled asthma i.e. symptoms of asthma (daytime or night-time) or use of
             short-acting beta agonist for relief of asthma (except with exercise) more than once a
             week

          -  Worsening of asthma signs and symptoms prompting a medical intervention within 1 year
             prior to dosing

          -  Severe atopic dermatitis within 1 year prior to dosing, defined by a history of
             eruption with severe inflammation such as erythema, papule, erosion, infiltration and
             lichen

          -  Severe allergic rhinitis strongly disturbing daily life within 1 year prior to dosing

          -  Severe allergic conjunctivitis (e.g., episodes of giant papillary, limbal
             proliferation, shield ulcer) within 1 year prior to dosing

          -  Prior use of Xolair® or other anti-IgE antibodies

          -  Concomitant use of allergy vaccination therapy

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>228-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy,</keyword>
  <keyword>Asthma,</keyword>
  <keyword>Atopic dermatitis,</keyword>
  <keyword>Japanese,</keyword>
  <keyword>QGE031,</keyword>
  <keyword>IgE</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

